Ionis Pharmaceuticals: latest news - GoINPHARMA
Saturday, 15 December 2018 - 6:25

Ionis Pharmaceuticals

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

NEJM publishes Phase III results for Biogen/Ionis’ Spinraza

Biogen and Ionis Pharmaceuticals have announced that final results from the Phase III clinical trial ENDEAR, aimed at assessing Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) have been published in the New England Journal of Medicine (NEJM)….

Alzheimer’s: Ionis Initiates phase I/II trial for antisense drug

Ionis Pharmaceuticals has initiated its Phase I//IIa clinical trial designed to test IONIS-MAPTRx in patients with moderate Alzheimer’s disease. Having initiated this study, Ionis will receive a $10m milestone payment from Biogen. IONIS-MAPTRx is an antisense drug designed to selectively…

Biogen and Ionis’ Spinraza confirms efficacy against SMA

Spinraza (nusinersen), a drug developed by Biogen Inc and Ionis Pharmaceuticals for treating SMA (spinal muscular atrophy) obtained remarkable results in the Phase III clinical trial CHERISH, which was even stopped, since the treatment met the primary endpoint. Ionis, indeed,…